Anifrolumab for Hidradenitis Suppurativa

Key Inclusion Criteria: * Must be at least 18 years of age and older. * Diagnosis or history of clinical features consistent with hidradenitis suppurativa for ≥6 months prior to baseline visit * Must have an inflammatory lesion count of ≥5 at the time of screening * Must be off oral and intravenous antibiotics or on a stable course of oral antibiotics for ≥28 days prior to the baseline visit. Allowable antibiotics during treatment course are topical clindamycin, topical chlorhexidine gluconate, oral doxycycline, oral minocycline, or oral clindamycin. * Must have hidradenitis suppurativa in at least two distinct body locations, i.e. left and right groin * Does not have a history of or current Tuberculosis (TB) Key Exclusion Criteria: * Have had surgical intervention beyond incision and drainage in the last 8 weeks or have open surgical wounds * Planning a major elective surgery during the time of the study. * Taking other immunomodulatory or biologic treatment for Hidradenitis Suppurativa * Previous treatment with anifrolumab for any reason. * Are pregnant, lactating, or intend to become pregnant or lactate for up to 16 weeks following the last dose of study drug upon signing the Informed Consent Form (ICF) * Severe herpes zoster infection * Known history of allergy or reaction to any component of the study drug * History of cancer (some cases of basal cell carcinoma and squamous cell carcinoma of the skin as well as cervical carcinoma in situ may be eligible). * Primary im…